List of Excipients in Branded Drug 40% OXYGEN/NITROGEN MIX

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
NexAir LLC	40% OXYGEN/NITROGEN MIX	40% oxygen/nitrogen mix	12213-200	NITROGEN

40% Oxygen/60% Nitrogen Medicinal Gas: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: October 26, 2026

A 40% oxygen/60% nitrogen mixture is better analyzed as a medicinal gas than as a conventional pharmaceutical drug. Nitrogen is the carrier gas, not a pharmacologically active excipient. The commercial opportunity depends on validated gas composition, cylinder or pipeline delivery, contamination control, stability, and regulatory positioning rather than on a traditional formulation strategy. The mixture itself is unlikely to support a strong composition-of-matter patent estate.

What is a 40% oxygen/nitrogen pharmaceutical product?

A 40% oxygen/nitrogen mixture contains approximately:

Component	Nominal concentration	Functional role
Oxygen	40% v/v	Active medicinal gas
Nitrogen	60% v/v	Diluent and carrier gas
Other components	0%, unless specified	Not part of the stated formulation

The product is generally intended for inhalation through a mask, nasal interface, ventilator, anesthesia system, or other delivery equipment. The oxygen concentration is materially higher than ambient air, which contains approximately 20.9% oxygen and 78.1% nitrogen.

The product should not be treated as an injectable formulation or as a conventional oral or sterile-liquid drug. Its quality profile is defined by gas identity, concentration, pressure, moisture, particulates, hydrocarbons, trace gases, container compatibility, and delivery accuracy.

What is the excipient strategy for a 40% oxygen/nitrogen mixture?

The core excipient strategy is to use no conventional excipients. Nitrogen is a formulation component and diluent, but it is not an excipient in the same sense as lactose, polysorbate, polyethylene glycol, or a tablet binder.

Is nitrogen an excipient or an active ingredient?

Nitrogen is best characterized as the carrier or balance gas. Its principal functions are:

• Diluting oxygen to the target concentration.
• Controlling delivered oxygen partial pressure.
• Supporting a stable, homogeneous gas mixture.
• Providing a nonflammable balance gas for storage and administration.
• Avoiding the use of ambient air, whose composition and contamination profile can vary.

The product specification should define nitrogen by concentration and purity, not by conventional excipient controls. Relevant controls include oxygen concentration, nitrogen balance, water content, carbon monoxide, carbon dioxide, hydrocarbons, sulfur compounds, particulates, and other trace contaminants.

What formulation components can improve commercial performance?

The main formulation choices are limited to the gas composition and delivery format:

Formulation or presentation choice	Commercial value	Main technical issue
40% oxygen/60% nitrogen	Defined oxygen therapy concentration	Concentration tolerance and blending accuracy
High-pressure cylinders	Portable and decentralized supply	Cylinder qualification and transport controls
Manifolded cylinder systems	Hospitals and clinics	Continuity of supply and changeover validation
Bulk liquid oxygen with on-site blending	Large facilities	Capital cost and calibration
Central pipeline supply	Hospitals and operating rooms	Infrastructure qualification
Single-use portable cartridges	Home and emergency use	Pressure, weight, and delivery duration
Premixed disposable bags or canisters	Controlled point-of-care use	Package integrity and leakage

Adding water vapor, carbon dioxide, helium, nitrous oxide, or other gases would create a different product and could materially change its clinical, regulatory, and patent profile. Such additions should not be treated as minor excipient modifications.

What quality specifications protect a 40% oxygen/nitrogen product?

The highest-value technical specifications relate to composition and delivery accuracy. A commercial specification should normally address:

1. Oxygen concentration and allowable range.
2. Nitrogen balance.
3. Pressure at release and pressure at administration.
4. Moisture content.
5. Particulate contamination.
6. Oil and hydrocarbon contamination.
7. Carbon monoxide and carbon dioxide.
8. Cylinder or container identity.
9. Valve compatibility.
10. Leak rate and residual pressure.
11. Homogeneity after filling.
12. Shelf life and concentration stability.

The United States Pharmacopeia identifies standards for medicinal gases and oxygen quality, while European medicinal-gas standards are addressed through the European Pharmacopoeia and national regulatory systems (United States Pharmacopeial Convention, n.d.; European Directorate for the Quality of Medicines & HealthCare, n.d.).

The principal stability risk is not chemical degradation of oxygen and nitrogen. It is loss of product integrity through leakage, permeation, incorrect filling, valve failure, contamination, mislabeling, or delivery-system error.

What patents protect a 40% oxygen/nitrogen mixture?

The 40% oxygen/60% nitrogen composition is unlikely to support a durable composition-of-matter patent. Both gases are known substances, and oxygen-enriched air mixtures have extensive prior art in respiratory care, anesthesia, industrial gas supply, and medical-gas delivery.

Potentially protectable subject matter includes:

Patent category	Potential strength	Examples of claim scope
Composition	Low	Defined oxygen concentration range with nitrogen balance
Gas blending	Moderate	Inline blending, mixing controls, calibration, or purity monitoring
Cylinder filling	Moderate	Filling sequence, pressure management, and homogenization
Delivery system	Moderate to strong	Flow control, oxygen-concentration maintenance, alarms
Ventilator integration	Moderate to strong	Closed-loop oxygen control and patient-specific delivery
Packaging	Moderate	Valve, regulator, tamper evidence, or pressure-retention structure
Manufacturing quality control	Moderate	In-process analytical testing and release procedures
Method of use	Variable	Use in specified patient populations or clinical settings
Digital monitoring	Potentially strong	Sensor-driven concentration control and remote monitoring

A patent strategy should therefore focus on the product system rather than the gas composition alone. The strongest claims are likely to cover a validated combination of premixed gas, container, regulator, sensor, and delivery protocol.

What is the FDA regulatory status of a 40% oxygen/nitrogen mixture?

FDA treatment depends on the intended use, labeling, manufacturing process, presentation, and delivery system. Oxygen is regulated as a drug when intended for medical use. FDA regulations address medical gases, including oxygen, in 21 C.F.R. § 201.328.

A 40% premixed oxygen/nitrogen product may require a drug application or another FDA-recognized regulatory pathway if it is marketed with therapeutic claims and does not fit an existing monograph or established product category. The regulatory analysis should distinguish:

• Bulk oxygen used by a healthcare facility.
• A premixed cylinder product.
• A gas supplied through a hospital pipeline.
• A product integrated into a ventilator or oxygen-concentration controller.
• A home-use product with a dedicated delivery device.

The delivery device can create a separate medical-device or combination-product issue. Labeling that claims treatment of hypoxemia, respiratory disease, anesthesia-related conditions, or other disease states increases the regulatory burden.

What is the Orange Book status of a 40% oxygen/nitrogen product?

No product-specific Orange Book status can be determined from the composition description alone. A branded product name, sponsor, application number, or recognized FDA listing is needed to identify a particular reference product.

For a generic applicant, the principal questions would be:

• Whether an FDA reference product exists.
• Whether the product is listed as a drug product in FDA databases.
• Whether the proposed product has the same active ingredients and concentration.
• Whether the container, valve, pressure, and delivery system are equivalent.
• Whether an abbreviated application pathway is available.
• Whether the product is approved under an NDA, ANDA, or another route.

A 40% oxygen/nitrogen mixture may face a regulatory-equivalence problem if the reference product uses a proprietary delivery system or if the approved product is defined by device performance rather than gas composition alone.

When does a 40% oxygen/nitrogen product lose exclusivity?

The gas composition has no meaningful exclusivity period in the conventional small-molecule sense. Exclusivity would arise from specific regulatory approvals, patents, trade secrets, device integration, or market access arrangements.

Potential exclusivity sources include:

Exclusivity source	Relevance
Composition patent	Weak for oxygen/nitrogen alone
Delivery-device patent	More important
Method-of-use patent	Dependent on a defined clinical indication
Regulatory exclusivity	Depends on application type and approval status
Orphan designation	Relevant only to a qualifying rare disease use
Manufacturing trade secret	Potentially important for blending and release
Hospital contract	Commercial rather than statutory exclusivity
Supply agreement	Can restrict access to cylinders or pipeline systems

Patent duration for a later-filed delivery or manufacturing patent is generally measured from its earliest effective nonprovisional filing date, subject to patent-term adjustment and any applicable regulatory extension. A precise expiration date cannot be assigned to the gas mixture without identified patent numbers.

What Paragraph IV challenges and generic-entry risks exist?

A Paragraph IV strategy would be relevant only if a listed reference product has patents in the FDA Orange Book. For a 40% oxygen/nitrogen mixture, the likely challenge targets would be:

• Delivery-device patents.
• Sensor and concentration-control patents.
• Filling and packaging patents.
• Method-of-use patents.
• Integrated ventilator-control patents.

The composition itself is a weak Paragraph IV target because a challenger could generally argue that oxygen/nitrogen mixtures and oxygen-enriched respiratory therapy were known before any product-specific filing.

Generic-entry risks are more likely to arise through:

1. A therapeutically equivalent premixed gas.
2. An authorized generic or private-label gas.
3. Hospital bulk-gas substitution.
4. A competing cylinder supplier.
5. An alternative oxygen-delivery system.
6. A device that produces the same concentration from separate gas sources.

The principal barrier is operational equivalence. A competing product must demonstrate consistent delivered concentration under expected flow rates, pressure conditions, temperature ranges, and device configurations.

What formulation patents and method-of-use patents could be valuable?

Formulation and manufacturing patents

Commercially relevant claims could cover:

• Oxygen concentration ranges centered on 40% oxygen.
• Defined impurity limits.
• Sequential filling procedures.
• Pressure-balancing methods.
• Mixing and homogenization steps.
• Cylinder passivation or surface treatment.
• Moisture-control methods.
• Automated release testing.
• Detection of concentration drift.
• Packaging that limits leakage or permeation.

These claims must overcome substantial prior art from industrial and medical-gas suppliers.

Method-of-use patents

Method-of-use protection could target a defined clinical protocol, such as:

• Controlled oxygen administration for a named disease.
• Use during a specific anesthesia protocol.
• Oxygen titration based on pulse oximetry or blood-gas measurements.
• Use in neonatal, emergency, intensive-care, or transport settings.
• Use with a particular ventilator or respiratory interface.

Clinical-use patents are vulnerable if the therapy is routine, the concentration is selected by standard practice, or the claimed benefit is not clearly tied to the 40% concentration.

Which companies could compete in this market?

The competitive landscape includes global industrial-gas companies, hospital-gas specialists, medical-device manufacturers, and regional cylinder suppliers. Relevant commercial capabilities include:

• Medical-gas production.
• Cylinder filling and testing.
• Hospital pipeline installation.
• Oxygen concentrator manufacturing.
• Ventilator integration.
• Respiratory monitoring.
• Home-care distribution.

Large industrial-gas suppliers such as Linde, Air Liquide, Air Products, and Messer have broad medical-gas infrastructure, although their participation in a specific 40% premixed product must be verified by product and jurisdiction. Device companies may compete by offering oxygen-control systems that reduce the need for a premixed cylinder.

The strongest commercial position may belong to a supplier that combines certified gas production with delivery hardware, hospital logistics, and service contracts.

What licensing deals and partnerships are most valuable?

Licensing opportunities are likely to involve systems, not the gas formula. High-value deal structures could cover:

Asset	Likely partner
Closed-loop oxygen controller	Ventilator or monitoring company
Premixed cylinder platform	Medical-gas distributor
Portable delivery system	Home-care or emergency-care supplier
Hospital pipeline integration	Hospital engineering contractor
Automated gas analyzer	Instrumentation company
Regional manufacturing rights	Industrial-gas producer
Clinical protocol	Hospital network or academic institution

A license should define territory, approved indications, device compatibility, cylinder ownership, quality responsibilities, pharmacovigilance, recalls, and control of regulatory submissions.

How strong is the patent estate for a 40% oxygen/nitrogen mixture?

The stand-alone composition has a weak patent position. The broader product platform can have moderate strength if it combines:

• A narrowly defined and clinically useful concentration.
• A validated delivery system.
• Proprietary sensors or control algorithms.
• A difficult-to-replicate manufacturing process.
• Regulatory approval tied to a specific presentation.
• Hospital contracts and distribution infrastructure.

The defensible value is therefore more likely to come from execution, compliance, and integrated delivery than from molecule-level exclusivity.

What commercial opportunities exist?

The most plausible opportunities are:

1. Hospital respiratory therapy.
2. Emergency medical transport.
3. Intensive-care and anesthesia systems.
4. Neonatal and pediatric respiratory care.
5. Home oxygen programs requiring controlled concentration.
6. Military and disaster-response medicine.
7. Remote clinics with limited bulk-gas infrastructure.
8. Clinical research requiring reproducible oxygen exposure.
9. Portable oxygen systems.
10. Contract manufacturing for regional medical-gas suppliers.

Revenue exposure depends on volume, cylinder turnover, refill frequency, device attachment, service contracts, and hospital procurement. Gas itself is often a lower-margin component than the regulator, monitor, delivery hardware, maintenance contract, or integrated respiratory platform.

Key Takeaways

• A 40% oxygen/60% nitrogen product is a medicinal gas, not a conventional excipient-based formulation.
• Nitrogen is the balance gas and carrier, not a conventional inactive ingredient.
• The gas composition alone is unlikely to support a strong composition patent.
• The strongest IP opportunities are in blending, filling, packaging, sensing, delivery, and clinical-use protocols.
• FDA status depends on intended use, presentation, delivery system, and the existence of a recognized reference product.
• Orange Book and Paragraph IV analysis requires an identified branded product and application.
• Generic-entry risk is driven by delivery-system substitution and hospital supply competition.
• Commercial value is likely to concentrate in integrated gas-plus-device platforms, supply infrastructure, and service contracts.

FAQs

Is 40% oxygen considered medical oxygen?

Yes. A gas containing 40% oxygen can be marketed for medical use if it meets applicable regulatory, purity, manufacturing, labeling, and delivery requirements. It is not equivalent to ambient air or standard 21% oxygen medical air.

Can nitrogen be replaced with medical air?

Replacing nitrogen with medical air changes the formulation because medical air contains oxygen and other components. The resulting oxygen concentration, impurity profile, and regulatory identity would require separate validation.

Can a 40% oxygen/nitrogen mixture be protected by a patent?

The basic mixture is unlikely to support strong composition protection. Patents are more credible for a specific manufacturing process, container, regulator, sensor, delivery algorithm, or clinical use.

Is a 40% oxygen mixture automatically eligible for an ANDA?

No. ANDA eligibility depends on the existence of a suitable FDA reference product and the ability to demonstrate pharmaceutical and, where relevant, device equivalence.

What is the main manufacturing barrier?

The principal barrier is validated control of concentration, purity, pressure, leakage, cylinder identity, and delivery accuracy across the product’s shelf life and intended use conditions.

References

European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Council of Europe. https://www.edqm.eu/en/european-pharmacopoeia

U.S. Food and Drug Administration. (n.d.). Medical gases. https://www.fda.gov/drugs/medical-gases

United States Pharmacopeial Convention. (n.d.). United States Pharmacopeia and National Formulary. https://www.usp.org/usp-nf

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

21 C.F.R. § 201.328. Oxygen.